Global Nucleic Acid-based Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 247506
  • calendar_today Published On: Dec, 2021
  • file_copy Pages: 156
  • list Technology
Buy @ $3500

The Nucleic Acid-based Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Nucleic Acid-based Drugs size is estimated to be USD million in 2026 from USD million in 2020, with a change % between 2020 and 2021. The global Nucleic Acid-based Drugs market size is expected to grow at a CAGR of % for the next five years.

Market segmentation

Nucleic Acid-based Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

ASO

mRNA

siRNA

miRNA

saRNA

Aptamer

Market segment by Application, can be divided into

Genetic Disease

Cancer

Cardiovascular Diseases

Other

Market segment by players, this report covers

Ionis Pharmaceuticals

Sarepta Therapeutics

Nippon Shinyaku

BioNTech

Moderna Therapeutics

CureVac

Alnylam Pharmaceuticals

Regulus Therapeutics

Miragen Therapeutics

Mina Therapeutics

NeXstar Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Nucleic Acid-based Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Nucleic Acid-based Drugs, with revenue, gross margin and global market share of Nucleic Acid-based Drugs from 2019 to 2021.

Chapter 3, the Nucleic Acid-based Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Nucleic Acid-based Drugs market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Nucleic Acid-based Drugs research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Nucleic Acid-based Drugs

1.2 Classification of Nucleic Acid-based Drugs by Type

1.2.1 Overview: Global Nucleic Acid-based Drugs Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2020

1.2.3 ASO

1.2.4 mRNA

1.2.5 siRNA

1.2.6 miRNA

1.2.7 saRNA

1.2.8 Aptamer

1.3 Global Nucleic Acid-based Drugs Market by Application

1.3.1 Overview: Global Nucleic Acid-based Drugs Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Genetic Disease

1.3.3 Cancer

1.3.4 Cardiovascular Diseases

1.3.5 Other

1.4 Global Nucleic Acid-based Drugs Market Size & Forecast

1.5 Global Nucleic Acid-based Drugs Market Size and Forecast by Region

1.5.1 Global Nucleic Acid-based Drugs Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Nucleic Acid-based Drugs Market Size by Region, (2016-2021)

1.5.3 North America Nucleic Acid-based Drugs Market Size and Prospect (2016-2026)

1.5.4 Europe Nucleic Acid-based Drugs Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Nucleic Acid-based Drugs Market Size and Prospect (2016-2026)

1.5.6 South America Nucleic Acid-based Drugs Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Nucleic Acid-based Drugs Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Nucleic Acid-based Drugs Market Drivers

1.6.2 Nucleic Acid-based Drugs Market Restraints

1.6.3 Nucleic Acid-based Drugs Trends Analysis

2 Company Profiles

2.1 Ionis Pharmaceuticals

2.1.1 Ionis Pharmaceuticals Details

2.1.2 Ionis Pharmaceuticals Major Business

2.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

2.1.4 Ionis Pharmaceuticals Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Ionis Pharmaceuticals Recent Developments and Future Plans

2.2 Sarepta Therapeutics

2.2.1 Sarepta Therapeutics Details

2.2.2 Sarepta Therapeutics Major Business

2.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.2.4 Sarepta Therapeutics Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Sarepta Therapeutics Recent Developments and Future Plans

2.3 Nippon Shinyaku

2.3.1 Nippon Shinyaku Details

2.3.2 Nippon Shinyaku Major Business

2.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions

2.3.4 Nippon Shinyaku Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Nippon Shinyaku Recent Developments and Future Plans

2.4 BioNTech

2.4.1 BioNTech Details

2.4.2 BioNTech Major Business

2.4.3 BioNTech Nucleic Acid-based Drugs Product and Solutions

2.4.4 BioNTech Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 BioNTech Recent Developments and Future Plans

2.5 Moderna Therapeutics

2.5.1 Moderna Therapeutics Details

2.5.2 Moderna Therapeutics Major Business

2.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.5.4 Moderna Therapeutics Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Moderna Therapeutics Recent Developments and Future Plans

2.6 CureVac

2.6.1 CureVac Details

2.6.2 CureVac Major Business

2.6.3 CureVac Nucleic Acid-based Drugs Product and Solutions

2.6.4 CureVac Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 CureVac Recent Developments and Future Plans

2.7 Alnylam Pharmaceuticals

2.7.1 Alnylam Pharmaceuticals Details

2.7.2 Alnylam Pharmaceuticals Major Business

2.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

2.7.4 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Alnylam Pharmaceuticals Recent Developments and Future Plans

2.8 Regulus Therapeutics

2.8.1 Regulus Therapeutics Details

2.8.2 Regulus Therapeutics Major Business

2.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.8.4 Regulus Therapeutics Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Regulus Therapeutics Recent Developments and Future Plans

2.9 Miragen Therapeutics

2.9.1 Miragen Therapeutics Details

2.9.2 Miragen Therapeutics Major Business

2.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.9.4 Miragen Therapeutics Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Miragen Therapeutics Recent Developments and Future Plans

2.10 Mina Therapeutics

2.10.1 Mina Therapeutics Details

2.10.2 Mina Therapeutics Major Business

2.10.3 Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions

2.10.4 Mina Therapeutics Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Mina Therapeutics Recent Developments and Future Plans

2.11 NeXstar Pharmaceuticals

2.11.1 NeXstar Pharmaceuticals Details

2.11.2 NeXstar Pharmaceuticals Major Business

2.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

2.11.4 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 NeXstar Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Nucleic Acid-based Drugs Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Nucleic Acid-based Drugs Players Market Share

3.2.2 Top 10 Nucleic Acid-based Drugs Players Market Share

3.2.3 Market Competition Trend

3.3 Nucleic Acid-based Drugs Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Nucleic Acid-based Drugs Revenue and Market Share by Type (2016-2021)

4.2 Global Nucleic Acid-based Drugs Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Nucleic Acid-based Drugs Revenue Market Share by Application (2016-2021)

5.2 Nucleic Acid-based Drugs Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Nucleic Acid-based Drugs Revenue by Type (2016-2026)

6.2 North America Nucleic Acid-based Drugs Revenue by Application (2016-2026)

6.3 North America Nucleic Acid-based Drugs Market Size by Country

6.3.1 North America Nucleic Acid-based Drugs Revenue by Country (2016-2026)

6.3.2 United States Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

6.3.3 Canada Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

6.3.4 Mexico Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Nucleic Acid-based Drugs Revenue by Type (2016-2026)

7.2 Europe Nucleic Acid-based Drugs Revenue by Application (2016-2026)

7.3 Europe Nucleic Acid-based Drugs Market Size by Country

7.3.1 Europe Nucleic Acid-based Drugs Revenue by Country (2016-2026)

7.3.2 Germany Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

7.3.3 France Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

7.3.5 Russia Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

7.3.6 Italy Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Nucleic Acid-based Drugs Revenue by Type (2016-2026)

8.2 Asia-Pacific Nucleic Acid-based Drugs Revenue by Application (2016-2026)

8.3 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region

8.3.1 Asia-Pacific Nucleic Acid-based Drugs Revenue by Region (2016-2026)

8.3.2 China Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

8.3.3 Japan Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

8.3.4 South Korea Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

8.3.5 India Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

8.3.7 Australia Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Nucleic Acid-based Drugs Revenue by Type (2016-2026)

9.2 South America Nucleic Acid-based Drugs Revenue by Application (2016-2026)

9.3 South America Nucleic Acid-based Drugs Market Size by Country

9.3.1 South America Nucleic Acid-based Drugs Revenue by Country (2016-2026)

9.3.2 Brazil Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

9.3.3 Argentina Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Nucleic Acid-based Drugs Revenue by Type (2016-2026)

10.2 Middle East & Africa Nucleic Acid-based Drugs Revenue by Application (2016-2026)

10.3 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country

10.3.1 Middle East & Africa Nucleic Acid-based Drugs Revenue by Country (2016-2026)

10.3.2 Turkey Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

10.3.4 UAE Nucleic Acid-based Drugs Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Nucleic Acid-based Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Nucleic Acid-based Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Nucleic Acid-based Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Nucleic Acid-based Drugs Revenue (USD Million) by Region (2016-2021)

Table 5. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2021-2026)

Table 6. Ionis Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 7. Ionis Pharmaceuticals Major Business

Table 8. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

Table 9. Ionis Pharmaceuticals Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors

Table 11. Sarepta Therapeutics Major Business

Table 12. Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 13. Sarepta Therapeutics Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Nippon Shinyaku Corporate Information, Head Office, and Major Competitors

Table 15. Nippon Shinyaku Major Business

Table 16. Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions

Table 17. Nippon Shinyaku Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. BioNTech Corporate Information, Head Office, and Major Competitors

Table 19. BioNTech Major Business

Table 20. BioNTech Nucleic Acid-based Drugs Product and Solutions

Table 21. BioNTech Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Moderna Therapeutics Corporate Information, Head Office, and Major Competitors

Table 23. Moderna Therapeutics Major Business

Table 24. Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 25. Moderna Therapeutics Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. CureVac Corporate Information, Head Office, and Major Competitors

Table 27. CureVac Major Business

Table 28. CureVac Nucleic Acid-based Drugs Product and Solutions

Table 29. CureVac Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 31. Alnylam Pharmaceuticals Major Business

Table 32. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

Table 33. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Regulus Therapeutics Corporate Information, Head Office, and Major Competitors

Table 35. Regulus Therapeutics Major Business

Table 36. Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 37. Regulus Therapeutics Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Miragen Therapeutics Corporate Information, Head Office, and Major Competitors

Table 39. Miragen Therapeutics Major Business

Table 40. Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 41. Miragen Therapeutics Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Mina Therapeutics Corporate Information, Head Office, and Major Competitors

Table 43. Mina Therapeutics Major Business

Table 44. Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions

Table 45. Mina Therapeutics Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. NeXstar Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 47. NeXstar Pharmaceuticals Major Business

Table 48. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions

Table 49. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Global Nucleic Acid-based Drugs Revenue (USD Million) by Players (2019-2021)

Table 51. Global Nucleic Acid-based Drugs Revenue Share by Players (2019-2021)

Table 52. Breakdown of Nucleic Acid-based Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 53. Nucleic Acid-based Drugs Players Head Office, Products and Services Provided

Table 54. Nucleic Acid-based Drugs Mergers & Acquisitions in the Past Five Years

Table 55. Nucleic Acid-based Drugs New Entrants and Expansion Plans

Table 56. Global Nucleic Acid-based Drugs Revenue (USD Million) by Type (2016-2021)

Table 57. Global Nucleic Acid-based Drugs Revenue Share by Type (2016-2021)

Table 58. Global Nucleic Acid-based Drugs Revenue Forecast by Type (2021-2026)

Table 59. Global Nucleic Acid-based Drugs Revenue by Application (2016-2021)

Table 60. Global Nucleic Acid-based Drugs Revenue Forecast by Application (2021-2026)

Table 61. North America Nucleic Acid-based Drugs Revenue by Type (2016-2021) & (USD Million)

Table 62. North America Nucleic Acid-based Drugs Revenue by Type (2021-2026) & (USD Million)

Table 63. North America Nucleic Acid-based Drugs Revenue by Application (2016-2021) & (USD Million)

Table 64. North America Nucleic Acid-based Drugs Revenue by Application (2021-2026) & (USD Million)

Table 65. North America Nucleic Acid-based Drugs Revenue by Country (2016-2021) & (USD Million)

Table 66. North America Nucleic Acid-based Drugs Revenue by Country (2021-2026) & (USD Million)

Table 67. Europe Nucleic Acid-based Drugs Revenue by Type (2016-2021) & (USD Million)

Table 68. Europe Nucleic Acid-based Drugs Revenue by Type (2021-2026) & (USD Million)

Table 69. Europe Nucleic Acid-based Drugs Revenue by Application (2016-2021) & (USD Million)

Table 70. Europe Nucleic Acid-based Drugs Revenue by Application (2021-2026) & (USD Million)

Table 71. Europe Nucleic Acid-based Drugs Revenue by Country (2016-2021) & (USD Million)

Table 72. Europe Nucleic Acid-based Drugs Revenue by Country (2021-2026) & (USD Million)

Table 73. Asia-Pacific Nucleic Acid-based Drugs Revenue by Type (2016-2021) & (USD Million)

Table 74. Asia-Pacific Nucleic Acid-based Drugs Revenue by Type (2021-2026) & (USD Million)

Table 75. Asia-Pacific Nucleic Acid-based Drugs Revenue by Application (2016-2021) & (USD Million)

Table 76. Asia-Pacific Nucleic Acid-based Drugs Revenue by Application (2021-2026) & (USD Million)

Table 77. Asia-Pacific Nucleic Acid-based Drugs Revenue by Region (2016-2021) & (USD Million)

Table 78. Asia-Pacific Nucleic Acid-based Drugs Revenue by Region (2021-2026) & (USD Million)

Table 79. South America Nucleic Acid-based Drugs Revenue by Type (2016-2021) & (USD Million)

Table 80. South America Nucleic Acid-based Drugs Revenue by Type (2021-2026) & (USD Million)

Table 81. South America Nucleic Acid-based Drugs Revenue by Application (2016-2021) & (USD Million)

Table 82. South America Nucleic Acid-based Drugs Revenue by Application (2021-2026) & (USD Million)

Table 83. South America Nucleic Acid-based Drugs Revenue by Country (2016-2021) & (USD Million)

Table 84. South America Nucleic Acid-based Drugs Revenue by Country (2021-2026) & (USD Million)

Table 85. Middle East & Africa Nucleic Acid-based Drugs Revenue by Type (2016-2021) & (USD Million)

Table 86. Middle East & Africa Nucleic Acid-based Drugs Revenue by Type (2021-2026) & (USD Million)

Table 87. Middle East & Africa Nucleic Acid-based Drugs Revenue by Application (2016-2021) & (USD Million)

Table 88. Middle East & Africa Nucleic Acid-based Drugs Revenue by Application (2021-2026) & (USD Million)

Table 89. Middle East & Africa Nucleic Acid-based Drugs Revenue by Country (2016-2021) & (USD Million)

Table 90. Middle East & Africa Nucleic Acid-based Drugs Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Nucleic Acid-based Drugs Picture

Figure 2. Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2020

Figure 3. ASO

Figure 4. mRNA

Figure 5. siRNA

Figure 6. miRNA

Figure 7. saRNA

Figure 8. Aptamer

Figure 9. Nucleic Acid-based Drugs Revenue Market Share by Application in 2020

Figure 10. Genetic Disease Picture

Figure 11. Cancer Picture

Figure 12. Cardiovascular Diseases Picture

Figure 13. Other Picture

Figure 14. Global Nucleic Acid-based Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 15. Global Nucleic Acid-based Drugs Revenue and Forecast (2016-2026) & (USD Million)

Figure 16. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2016-2026)

Figure 17. Global Nucleic Acid-based Drugs Revenue Market Share by Region in 2020

Figure 18. North America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Europe Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Asia-Pacific Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. South America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. Middle East and Africa Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 23. Nucleic Acid-based Drugs Market Drivers

Figure 24. Nucleic Acid-based Drugs Market Restraints

Figure 25. Nucleic Acid-based Drugs Market Trends

Figure 26. Ionis Pharmaceuticals Recent Developments and Future Plans

Figure 27. Sarepta Therapeutics Recent Developments and Future Plans

Figure 28. Nippon Shinyaku Recent Developments and Future Plans

Figure 29. BioNTech Recent Developments and Future Plans

Figure 30. Moderna Therapeutics Recent Developments and Future Plans

Figure 31. CureVac Recent Developments and Future Plans

Figure 32. Alnylam Pharmaceuticals Recent Developments and Future Plans

Figure 33. Regulus Therapeutics Recent Developments and Future Plans

Figure 34. Miragen Therapeutics Recent Developments and Future Plans

Figure 35. Mina Therapeutics Recent Developments and Future Plans

Figure 36. NeXstar Pharmaceuticals Recent Developments and Future Plans

Figure 37. Global Nucleic Acid-based Drugs Revenue Share by Players in 2020

Figure 38. Nucleic Acid-based Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 39. Global Top 3 Players Nucleic Acid-based Drugs Revenue Market Share in 2020

Figure 40. Global Top 10 Players Nucleic Acid-based Drugs Revenue Market Share in 2020

Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 42. Global Nucleic Acid-based Drugs Revenue Share by Type in 2020

Figure 43. Global Nucleic Acid-based Drugs Market Share Forecast by Type (2021-2026)

Figure 44. Global Nucleic Acid-based Drugs Revenue Share by Application in 2020

Figure 45. Global Nucleic Acid-based Drugs Market Share Forecast by Application (2021-2026)

Figure 46. North America Nucleic Acid-based Drugs Sales Market Share by Type (2016-2026)

Figure 47. North America Nucleic Acid-based Drugs Sales Market Share by Application (2016-2026)

Figure 48. North America Nucleic Acid-based Drugs Revenue Market Share by Country (2016-2026)

Figure 49. United States Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 50. Canada Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. Mexico Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. Europe Nucleic Acid-based Drugs Sales Market Share by Type (2016-2026)

Figure 53. Europe Nucleic Acid-based Drugs Sales Market Share by Application (2016-2026)

Figure 54. Europe Nucleic Acid-based Drugs Revenue Market Share by Country (2016-2026)

Figure 55. Germany Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. France Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. United Kingdom Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. Russia Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. Italy Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. Asia-Pacific Nucleic Acid-based Drugs Sales Market Share by Type (2016-2026)

Figure 61. Asia-Pacific Nucleic Acid-based Drugs Sales Market Share by Application (2016-2026)

Figure 62. Asia-Pacific Nucleic Acid-based Drugs Revenue Market Share by Region (2016-2026)

Figure 63. China Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Japan Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. South Korea Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. India Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Southeast Asia Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. Australia Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. South America Nucleic Acid-based Drugs Sales Market Share by Type (2016-2026)

Figure 70. South America Nucleic Acid-based Drugs Sales Market Share by Application (2016-2026)

Figure 71. South America Nucleic Acid-based Drugs Revenue Market Share by Country (2016-2026)

Figure 72. Brazil Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Argentina Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. Middle East and Africa Nucleic Acid-based Drugs Sales Market Share by Type (2016-2026)

Figure 75. Middle East and Africa Nucleic Acid-based Drugs Sales Market Share by Application (2016-2026)

Figure 76. Middle East and Africa Nucleic Acid-based Drugs Revenue Market Share by Country (2016-2026)

Figure 77. Turkey Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 78. Saudi Arabia Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 79. UAE Nucleic Acid-based Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 80. Methodology

Figure 81. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz